Header graphic for print
The Healthcare Investor Insights on Issues & Trends that Impact Investments in Healthcare & Life Science Businesses

Healthcare & Life Sciences Private Equity Deal Tracker: Metabolon Secures $15 Million in Financing

Posted in Healthcare Services Investing

Metabolon, Inc. has announced it has raised $15 million in a series E financing.

Metabolon, headquartered in Research Triangle Park, N.C., provides metabolomics-based diagnostic tests and research services.

New investor Camden Partners, a Baltimore-based PE firm, led the round, with participation from Sumitomo Corp. along with existing investors Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners.

The funding is expected to support, among other things, Metabolon partner Bostwick Laboratories’ launch of Prostarix, a urine-based test that provides metabolic information on the likelihood that a patient with slightly elevated PSA scores has prostate cancer; the continued development of Metabolon’s Quantose IGT, a surrogate test for oral glucose tolerance; and Metabolon’s test for the recurrence of bladder cancer.

We use cookies to enhance your experience of our website. By continuing to use this website, you agree to the use of these cookies. For more information and to learn how you can change your cookie settings, please see our policy.